Patients benefit as the Royal Hospital for Neuro-disability introduces innovative predictive technology to support earlier recognition of infection risk

• Early real-world evidence shows MEMORI is being used in routine care and helping clinical teams identify patients at risk sooner
• Co-designed with RHN clinicians and embedded into the hospital's electronic patient record
• Sanome's MEMORI is among the first Class IIb certified AI clinical decision support platforms deployed in a UK hospital
  

LONDON, UK [6th of May 2026] - Sanome, a UK healthtech company, and The Royal Hospital for Neuro-disability (RHN), a London-based hospital that provides specialist care for people with neuro-disability, today announced early results from the first real-world implementation of MEMORI, Sanome’s AI-powered clinical decision support platform.

MEMORI is a Class IIb CE-certified (EU MDR) and MHRA-registered Software as a Medical Device, designed to support earlier recognition of infection risk in highly vulnerable patient populations. It is now live across three neuro-rehabilitation and ventilator wards at the RHN, integrated directly into the hospital's PatientSource electronic patient record system.

Why earlier recognition matters at the RHN

For patients at the RHN, many living with acquired brain injury and other complex neurological conditions, infection can be harder to detect. Signs of deterioration may be subtle, atypical, or difficult to communicate. Delays in recognition can interrupt rehabilitation, prolong recovery, and increase the need for escalation to acute care. MEMORI was introduced to give clinical teams richer, earlier insight – supporting intervention before deterioration becomes obvious.

How MEMORI works in practice

Integrated directly into the hospital’s PatientSource electronic patient record (EPR), MEMORI analyses multimodal hospital data, including vitals, observations and medications, to surface real-time, actionable and clinically relevant insight directly within the existing EPR workflow. The platform acts as a clinical co-pilot, helping doctors and nurses understand which patients may be at risk of infection, why, and what action to consider next, while keeping decision-making with the clinical team. 

Sanome takes a unique approach to implementation: clinical co-design and deep EPR integration. MEMORI was configured with frontline teams so that the way risk is surfaced, the recommended actions, and the best-practice advisories reflect local practice and the complexity of the RHN patient population. 

As Cameron Davey, Matron for Brain Injury Service at the Royal Hospital for Neuro-disability, put it: “The best practice advisories embedded in MEMORI were written by our own clinical teams. That clinical ownership made a real difference to how staff received it.”

Adopted in routine care

That clinical ownership has translated into one of the most important early signals of success: adoption. Whether a health technology delivers real impact depends on whether clinical teams actually use it. Evidence from RHN indicates MEMORI fits naturally into routine practice. Sustained engagement and positive staff feedback point to a technology that is being used in a clinically relevant way, within the workflow teams already know. 

Benedikt von Thüngen, CEO and Founder of Sanome added: “These results matter because they show that successful clinical AI implementation starts well before go-live. Too many tools are added on top of clinical work. What we have done at the RHN is different. MEMORI was co-designed so that it fits the realities of frontline workflow, reflects local practice, and earns trust from the people using it. That is what drives adoption. And adoption is what creates impact – supporting earlier recognition for a patient group where every hour counts.”

Safe, reliable, and clinically meaningful

The first three months have also been reassuring on safety and reliability. Post-market clinical follow-up has identified no adverse events, no evidence of inappropriate antibiotic prescribing, and no indication that MEMORI has replaced clinical judgement. The platform surfaces clinically meaningful signals without adding unnecessary noise.

MEMORI has been shown, in retrospective studies, to detect infection-related deterioration up to 72 hours earlier than standard early warning tools. Real-world analysis at RHN is consistent with this finding, suggesting that MEMORI can provide meaningful warning before physiological deterioration becomes obvious. That earlier window gives clinicians more time to intervene, supporting safer care and better patient outcomes.

Steven Luttrell, Medical Director at the Royal Hospital for Neuro-disability, said: “We pride ourselves on delivering the very best care to the patients we support and have a long legacy of caring for some of the most vulnerable people in the UK. Technology and innovation continually give us new ways to raise the bar, and MEMORI has helped us do that by giving our teams richer insight to support care and earlier intervention. Ultimately, that means a better opportunity to protect recovery and improve outcomes for our patients.”

What’s next

Further deployments in 2026 using the same principles of clinical co-design, local configuration, and Trust EPR integration, will include East Kent Hospitals University NHS Foundation Trust and Royal Devon University Healthcare NHS Foundation Trust.